m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis
Pulmonary Pharmacology & Therapeutics · 2026
DOI: 10.1016/j.pupt.2026.102438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026. Verfasst von Xiao-Mang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Guilin Medical University, Guilin, 541004, Guangxi, China. Hauptthemen laut MEDLINE: Asthma, Airway Remodeling, RNA-Binding Proteins, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 42 Literaturangaben. Gefördert von: Guilin Medical University, Specific Research Project of Guangxi for Research Bases and Talents, National Natural Science Foundation of China.
Abstract (Originalsprache)
N6-methyladenosine (m6A) modification is a crucial post-transcriptional regulatory mechanism for gene expression. In our previous bioinformatic analysis, we found that many m6A genes are involved in asthma pathogenesis; however, the precise regulatory mechanism has not been experimentally validated. Using an in-vitro asthma model (platelet-derived growth factor [PDGF]-BB-stimulated rat airway smooth muscle cells [AMSCs]), we validated dysregulated m6A-related genes using qRT-PCR. Functional assays (CCK-8 and wound healing assays) revealed that Igf2bp2 knockdown suppressed AMSC proliferation and migration. Integrated analysis of mRNA-sequencing (Igf2bp2-silenced AMSCs) and RIP-seq identified three asthma-associated targets: Dact1, Dixdc1, and Pdk4. Intriguingly, Dixdc1 transcripts harbored multiple m6A motifs, consistent with the RIP-seq data. Actinomycin D assays demonstrated the IGF2BP2-mediated post-transcriptional stabilization of Dixdc1 mRNA, a mechanism corroborated by both PDGF-BB-treated AMSCs and ovalbumin-induced asthmatic rats. Clinically, IGF2BP2-DIXDC1 co-expression was evident in the GEO human airway datasets and asthmatic rat tissues. Pharmacologically, resveratrol attenuated asthmatic phenotypes by suppressing this axis. Our findings delineate an m6A-dependent pathway, wherein IGF2BP2 stabilized Dixdc1 to drive airway remodeling, positioning resveratrol as a potential therapeutic agent targeting epitranscriptomic dysregulation in asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guilin Medical University, Guilin, 541004, Guangxi, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
- Respiratory Disease Laboratory, The First Affiliated Hospital of Guilin Medical University, Guilin, 541004, Guangxi, China.
- Guilin Medical University, Guilin, 541004, Guangxi, China. Electronic address: huiminliwork@qq.com.
Förderung
- Guilin Medical University
- Specific Research Project of Guangxi for Research Bases and Talents
- National Natural Science Foundation of China
Zitieren
APA
Li, X. M., Mo, B. W., Gao, Y., Chen, Y. X., Xiao, B., Gu, Y., Liang, M. M., & Li, H. M. (2026). m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis. Pulmonary Pharmacology & Therapeutics. https://doi.org/10.1016/j.pupt.2026.102438
Vancouver
Li XM, Mo BW, Gao Y, Chen YX, Xiao B, Gu Y, et al. m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis. Pulmonary Pharmacology & Therapeutics. 2026. doi:10.1016/j.pupt.2026.102438
BibTeX
@article{Li2026,
author = {Li, Xiao-Mang and Mo, Bi-Wen and Gao, Yan and Chen, Yun-Xiang and Xiao, Bo and Gu, Yue and Liang, Miao-Miao and Li, Hui-Min},
title = {m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1016/j.pupt.2026.102438}
}
EUVIMED